Sign in
Taking peopleNo phase

MRI blood-flow scan to tell tumor regrowth from radiation damage in brain metastases

Tests an MRI scan for brain metastases after Gamma Knife treatment.

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
ASL in Brain Metastasis MRI Following Gamma Knife Treatment
Status
Recruiting
People taking part
60 people, planned
Started
24 Jan 2023
Expected to end
24 Sept 2028
Type of study
Interventional
Treatments tested
  • MRI perfusion sequence
Record updated
8 August 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with brain metastases treated with Gamma Knife within the last 4 month, whose lesions have grown. The study tests an MRI method (ASL) to tell tumour growth from radiation damage.

Age
18 Years and older
Sex
All sexes
Disease stage
Brain metastasis (cancer spread to the brain) from a tumour confirmed by tissue test. The lesion has grown by ≥ 25% in size. The contrast-enhanced part of the lesion is ≥1 cm (0.4 in).
Earlier treatment
Gamma Knife treatment within 4 month before joining.

Main reasons for not taking part

  • Pregnancy
  • Past primary brain tumour
  • Cannot have MRI, or allergy to contrast agent, or claustrophobia
  • Epilepsy or recent stroke
  • Taking part in other studies, unable to consent, or no health insurance

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Brain metastasis from histologically proven tumor
  • GK treatment within 4 month prior to the inclusion
  • Lesions suspected of progression/ radionecrosis :; i.e.≥ 25% of the size progression
  • Lesion size: gadolinium enhanced part of the tumour ≥1 cm

Who cannot take part

  • Medical history of primitive brain tumour
  • MRI incompatibility/ medical history of contrast agent allergy
  • Epilepsia/recent stroke
  • Pregnancy
  • Claustrophobia
  • Patient unable to consent
  • Patients participating in other studies
  • Patients without health care insurance

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Arterial spin labeling (ASL) is a non-invasive MRI technique that could help the radiologists to distinguish brain metastasis progression versus radionecrosis following gamma-knife treatment.

Read full original descriptionShow less

The primary target of the study is to establish the diagnostic performances (specificity, sensitivity) of quantitative measures of ASL in brain metastases suspected of progression/radionecrosis after GK treatment

The group in the trial

  • Adults with brain metastases treated with Gamma Knife whose lesions suggest tumor recurrence versusTreatment being tested

    Inclusion visit, 1 month later, 6 month later

    Treatment: MRI perfusion sequence

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
ASL in Diagnostics of Tumor Progression Versus Radionecrosis in Brain Metastasis Following Gamma Knife Treatment.
Plain-language title
MRI blood-flow scan to tell tumor regrowth from radiation damage in brain metastasesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
8 August 2025